RU98117673A - Фармкомпозиция для лечения и/или профилактики гипергликемии, соль малеиновой кислоты 5-[4-[2-(n-метил-n-(2-пиридил)амино) этокси] бензил] тиазолидин-2, 4-диона или ее изомерная или таутомерная форма для лечения диабета ii типа - Google Patents

Фармкомпозиция для лечения и/или профилактики гипергликемии, соль малеиновой кислоты 5-[4-[2-(n-метил-n-(2-пиридил)амино) этокси] бензил] тиазолидин-2, 4-диона или ее изомерная или таутомерная форма для лечения диабета ii типа Download PDF

Info

Publication number
RU98117673A
RU98117673A RU98117673/14A RU98117673A RU98117673A RU 98117673 A RU98117673 A RU 98117673A RU 98117673/14 A RU98117673/14 A RU 98117673/14A RU 98117673 A RU98117673 A RU 98117673A RU 98117673 A RU98117673 A RU 98117673A
Authority
RU
Russia
Prior art keywords
amino
ilcene
imidene
treatment
dione
Prior art date
Application number
RU98117673/14A
Other languages
English (en)
Inventor
Колин Рипли Пул (GB)
Колин Рипли Пул
Робин Шервуд Роман (US)
Робин Шервуд Роман
Малькольм Дэвид Брайвелл (GB)
Малькольм Дэвид Брайвелл
Алан Уильям Тремпер (US)
Алан Уильям Тремпер
Original Assignee
Смитклайн Бичам Плс (Gb)
Смитклайн Бичам Плс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10721461&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU98117673(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Смитклайн Бичам Плс (Gb), Смитклайн Бичам Плс filed Critical Смитклайн Бичам Плс (Gb)
Publication of RU98117673A publication Critical patent/RU98117673A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Claims (4)

1. Фармацевтическая композиция для лечения и/или профилактики гипергликемии, отличающаяся тем, что в качестве активного ингредиента содержит соль малеиновой кислоты 5-[4-[2-(N-мeтил-N-(2-пиpидил)аминo)этoкcи] бeнзил] тиaзoлидин-2,4-диона или его изомерную или таутомерную форму и/или его фармацевтически приемлемый сольват, в эффективном количестве, а также фармацевтически приемлемый носитель.
2. Фармацевтическая композиция по п. 1 для лечения диабета П типа.
3. Соль малеиновой кислоты 5-[4-[2-(N-метил-N-(2-пиридил)амино)этокси] бензил] тиазолидин-2,4-диона или же ее изомерная или таутомерная форма и/или ее фармацевтически приемлемый сольват для использования для лечения и/или профилактики гипергликемии.
4. Соль малеиновой кислоты 5-[4-[2-(N-метил-N-(2-пиридил)амино)этокси] бензил]тиазолидин-2,4-диона или ее изомерная или таутомерная форма для лечения диабета П типа.
RU98117673/14A 1992-09-05 1998-09-24 Фармкомпозиция для лечения и/или профилактики гипергликемии, соль малеиновой кислоты 5-[4-[2-(n-метил-n-(2-пиридил)амино) этокси] бензил] тиазолидин-2, 4-диона или ее изомерная или таутомерная форма для лечения диабета ii типа RU98117673A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9218830.9 1992-09-05
GB929218830A GB9218830D0 (en) 1992-09-05 1992-09-05 Novel compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU95108329A Division RU2128179C1 (ru) 1992-09-05 1993-09-01 Замещенные производные тиазолидиндиона и способ их получения

Publications (1)

Publication Number Publication Date
RU98117673A true RU98117673A (ru) 2000-07-20

Family

ID=10721461

Family Applications (3)

Application Number Title Priority Date Filing Date
RU95108329A RU2128179C1 (ru) 1992-09-05 1993-09-01 Замещенные производные тиазолидиндиона и способ их получения
RU98117673/14A RU98117673A (ru) 1992-09-05 1998-09-24 Фармкомпозиция для лечения и/или профилактики гипергликемии, соль малеиновой кислоты 5-[4-[2-(n-метил-n-(2-пиридил)амино) этокси] бензил] тиазолидин-2, 4-диона или ее изомерная или таутомерная форма для лечения диабета ii типа
RU98117628/04A RU98117628A (ru) 1992-09-05 1998-09-24 Замещенные производные тиазолидиндиона, способ их получения, фармкомпозиция

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU95108329A RU2128179C1 (ru) 1992-09-05 1993-09-01 Замещенные производные тиазолидиндиона и способ их получения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU98117628/04A RU98117628A (ru) 1992-09-05 1998-09-24 Замещенные производные тиазолидиндиона, способ их получения, фармкомпозиция

Country Status (38)

Country Link
US (1) US5910592A (ru)
EP (2) EP0960883A1 (ru)
JP (5) JP2828777B2 (ru)
KR (3) KR20030097596A (ru)
CN (4) CN1040323C (ru)
AP (1) AP513A (ru)
AT (1) ATE182147T1 (ru)
AU (1) AU674880B2 (ru)
BR (1) BR1100916A (ru)
CA (2) CA2143849C (ru)
CY (1) CY2138B1 (ru)
CZ (2) CZ287473B6 (ru)
DE (2) DE69325658T2 (ru)
DK (1) DK0658161T3 (ru)
ES (1) ES2133410T3 (ru)
FI (2) FI106263B (ru)
GB (1) GB9218830D0 (ru)
GR (1) GR3030794T3 (ru)
HK (1) HK1012363A1 (ru)
HU (2) HU224212B1 (ru)
IL (1) IL106904A (ru)
LU (1) LU90712I2 (ru)
MA (1) MA22970A1 (ru)
MX (1) MX9305397A (ru)
MY (1) MY111190A (ru)
NL (1) NL300035I2 (ru)
NO (4) NO303016B1 (ru)
NZ (1) NZ255505A (ru)
PL (1) PL173725B1 (ru)
RU (3) RU2128179C1 (ru)
SA (1) SA93140245B1 (ru)
SG (2) SG83747A1 (ru)
SI (1) SI9300452B (ru)
SK (1) SK280777B6 (ru)
TW (1) TW385309B (ru)
UA (1) UA41901C2 (ru)
WO (1) WO1994005659A1 (ru)
ZA (1) ZA936509B (ru)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9308487D0 (en) * 1993-04-23 1993-06-09 Smithkline Beecham Plc Novel compounds
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5889025A (en) * 1996-05-06 1999-03-30 Reddy's Research Foundation Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5889032A (en) * 1996-05-06 1999-03-30 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
USRE39266E1 (en) * 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
CZ298812B6 (cs) 1996-07-01 2008-02-13 Dr. Reddy's Laboratories Limited Azolidindionové deriváty, způsob jejich přípravy, farmaceutické kompozice s jejich obsahem a jejich použití v léčbě diabetu a příbuzných nemocí
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6114526A (en) 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
JP2000514807A (ja) * 1996-07-12 2000-11-07 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー レプチン耐性の新規な治療
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
PL195136B1 (pl) * 1997-06-18 2007-08-31 Smithkline Beecham Plc Kombinacja zawierająca 5-[4-[2-(N-metylo-N-(2-pirydylo)amino)etoksy]-benzylo] tiazolidyno-2,4-dion i jej zastosowanie
AP1600A (en) * 1997-06-18 2006-04-28 Smithkline Beecham Plc Combination of a thiazolidinedione and a sulphonylurea for treating diabetes
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9721693D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
US20020006939A1 (en) * 1997-10-13 2002-01-17 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
US20010031776A1 (en) * 1997-10-13 2001-10-18 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
US7091359B2 (en) 1997-11-04 2006-08-15 Smithkline Beecham Plc Process for the preparation of thiazolidinedione derivatives
GB9723295D0 (en) 1997-11-04 1998-01-07 Smithkline Beecham Plc Novel process
AU774613B2 (en) * 1997-12-16 2004-07-01 Smithkline Beecham Plc Hydrate of 5-(4-(2- (N-methyl-N- (2-pyridil)amino) ethoxy)benzyl) thiazolidine-2,4-dione maleic acid salt
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726568D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
AU770817B2 (en) * 1997-12-16 2004-03-04 Smithkline Beecham Plc 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl) thiazolidine-2,dione,maleic acid salt, hydrate as pharmaceutical
GB9726566D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726563D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US6613785B2 (en) 1998-07-21 2003-09-02 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
AP2001002036A0 (en) * 1998-07-21 2001-03-31 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing apoptosis.
MA26662A1 (fr) * 1998-07-21 2004-12-20 Smithkline Beecham Plc Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
AR023699A1 (es) 1998-11-12 2002-09-04 Smithkline Beecham Corp Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
EP1813273A1 (en) * 1998-11-12 2007-08-01 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
GB9909041D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
GB9909075D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
PL351686A1 (en) * 1999-04-23 2003-06-02 Smithkline Beecham Plc Novel pharmaceutical
UA67845C2 (ru) * 1999-04-23 2004-07-15 Smithkline Beecham Plc Полиморф 5-[4-[2- (n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона соли малеиновой кислоты
AU765005B2 (en) * 1999-04-23 2003-09-04 Smithkline Beecham Plc Polymorph of 5-(4-(2- (N-methyl-N-( 2-pyridyl)amino) ethoxy)benzyl) thiazolidine-2,4-dione, maleic acid salt
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
JP2003507379A (ja) * 1999-08-17 2003-02-25 スミスクライン ビーチャム パブリック リミテッド カンパニー チアゾリジンジオン誘導体を含有する医薬組成物およびその調製法
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
GB0006133D0 (en) * 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
GB0014005D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
GB0014006D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
JP2004503499A (ja) * 2000-06-16 2004-02-05 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー 心臓のインスリン耐性に付随する症状の治療および予防
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
GB0019226D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0019223D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
AU2005229687B2 (en) * 2000-08-04 2008-03-13 Smithkline Beecham P.L.C. Tartrate salts of thiazolidinedione derivative
GB0019224D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
AU2005229688B2 (en) * 2000-08-04 2008-04-03 Smithkline Beecham P.L.C. Tartrate salts of thiazolidinedione derivative
GB0019228D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0021784D0 (en) * 2000-09-05 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021785D0 (en) * 2000-09-05 2000-10-18 Smithkline Beecham Plc Novel Pharmaceutical
GB0021865D0 (en) * 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
US7241895B2 (en) 2000-09-26 2007-07-10 Dr. Reddy's Laboratories Limited Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
WO2002026737A1 (en) * 2000-09-26 2002-04-04 Dr. Reddy's Research Foundation Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
GB0023971D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
US20040082620A1 (en) 2000-12-22 2004-04-29 Craig Andrew Simon 5'-4-'2-(n-methyl-n-(2-pyridyl)amino)ethoxy!benzyl!thiazolidine-2, 4-dione mesylate salt
WO2002051823A1 (en) 2000-12-26 2002-07-04 Torrent Pharmaceuticals Ltd Process for the preparation of rosiglitazone maleate
GB0127805D0 (en) 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
ATE329914T1 (de) * 2001-11-21 2006-07-15 Smithkline Beecham Plc Rosiglitazon-edisylate und ihre verwendung als antidiabetika
JP2005513038A (ja) * 2001-11-21 2005-05-12 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー ５−［４−［２−（ｎ−メチル−ｎ−（２−ピリジル）アミノ）エトキシ］ベンジル］チアゾリジン−２，４−ジオンベンゼンスルホン酸塩；その製造方法；多形体ｉ、ｉｉおよびｉｉｉ；および医薬上活性な成分としてのその使用
GB0129851D0 (en) * 2001-12-13 2002-01-30 Smithkline Beecham Plc Novel compounds
GB0129872D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
AU2002352391A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
AU2002352479A1 (en) * 2001-12-20 2003-07-09 Smithkline Beecham Plc 5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus
GB0130511D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130510D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
WO2004062667A1 (en) * 2003-01-08 2004-07-29 Dr. Reddy's Laboratories Limited Amorphous form of rosiglitazone maleate and process for preparation thereof
GB0307259D0 (en) * 2003-03-28 2003-05-07 Glaxo Group Ltd Process
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
WO2005058813A2 (en) * 2003-12-17 2005-06-30 Ranbaxy Laboratories Limited Thiodiazolidinedione, oxazolidinedione and diazolidinedione derivatives and their use as antidiabetic agents
EP1732513A2 (en) * 2003-12-31 2006-12-20 Alpharma, Inc. Rosiglitazone formulations
WO2005073227A2 (en) * 2004-01-28 2005-08-11 Usv Limited A process for the preparation of 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] phenyl methyl] thiazolidine-2, 4-dione maleate
GB2421240A (en) * 2004-12-14 2006-06-21 Sandoz Ag Phosphoric acid salt of rosiglitazone
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
GB2410948A (en) * 2004-02-13 2005-08-17 Sandoz Ag Novel phosphoric acid salt of rosiglitazone
CZ296468B6 (cs) * 2004-06-10 2006-03-15 Zentiva, A. S. Sul kyseliny fosforecné s 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dionema zpusob její prípravy
CZ2004844A3 (cs) * 2004-07-27 2006-03-15 Zentiva, A. S Sul kyseliny stavelové s 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dionu azpusob její prípravy a její pouzití
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
DE102005034406A1 (de) * 2005-07-22 2007-02-01 Ratiopharm Gmbh Neue Salze von Rosiglitazon
KR100749219B1 (ko) * 2006-03-15 2007-08-13 건일제약 주식회사 신규한 로지글리타존 옥살산염, 이의 제조방법, 및 이를포함하는 약제학적 조성물
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
JP2010502670A (ja) 2006-09-07 2010-01-28 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 真性糖尿病のための組合せ治療
US7645616B2 (en) 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
EP1967182A1 (en) * 2007-03-07 2008-09-10 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a salt of rosigliatazone
MX2009013354A (es) 2007-06-04 2010-07-06 Univ Ben Gurion Compuestos de triarilo y composiciones que los contienen.
CN101167726B (zh) * 2007-10-16 2011-05-18 宁夏康亚药业有限公司 马来酸罗格列酮分散片及其制备方法
PL384446A1 (pl) * 2008-02-12 2009-08-17 Adamed Spółka Z Ograniczoną Odpowiedzialnością Sól 5-[[4-[2-(metylo-2-pirydynyloamino)etoksy]fenylo]metylo]-2,4-tiazolidynodionu z kwasem malonowym i sposób jej wytwarzania
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate
DE102009053562A1 (de) 2009-11-18 2011-05-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
CN102532122B (zh) * 2010-12-29 2015-12-02 开封制药(集团)有限公司 酒石酸罗格列酮的制备方法
CA2928725A1 (en) 2013-11-05 2015-05-14 Esther Priel Compounds for the treatment of diabetes and disease complications arising from same
US10034868B2 (en) 2014-11-04 2018-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
IT201800002630A1 (it) * 2018-02-13 2019-08-13 Giuliani Spa Composizione per la prevenzione e il trattamento dei disturbi della crescita dei capelli

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4197297A (en) * 1976-11-17 1980-04-08 Smithkline Corporation 6-Halo-7,8-dihydroxy-1-(hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepines
US4405211A (en) * 1980-07-29 1983-09-20 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Liquid crystal compositions with pleochroic anthraquinone dyes
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5039687A (en) * 1985-12-04 1991-08-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyrrol-1-yl)pyridinamine compounds having enhancing activity
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US5232925A (en) * 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
HUT72639A (en) 1996-05-28
EP0658161A1 (en) 1995-06-21
CN1063942C (zh) 2001-04-04
KR20030097596A (ko) 2003-12-31
AU674880B2 (en) 1997-01-16
CA2143849A1 (en) 1994-03-17
EP0960883A1 (en) 1999-12-01
AP513A (en) 1996-07-30
SA93140245B1 (ar) 2005-10-15
TW385309B (en) 2000-03-21
CZ290591B6 (cs) 2002-08-14
NO950852L (no) 1995-03-03
AP9300562A0 (en) 1993-10-31
NL300035I1 (nl) 2001-03-01
JP2004359676A (ja) 2004-12-24
DE10199002I2 (de) 2001-12-13
EP0658161B1 (en) 1999-07-14
IL106904A0 (en) 1993-12-28
NO974646D0 (no) 1997-10-08
CN1183275A (zh) 1998-06-03
NO974646L (no) 1995-03-03
UA41901C2 (ru) 2001-10-15
NL300035I2 (nl) 2001-07-02
WO1994005659A1 (en) 1994-03-17
CY2138B1 (en) 2002-06-21
CA2143849C (en) 2000-04-25
SK27795A3 (en) 1995-08-09
DE69325658T2 (de) 1999-12-30
JP2008208142A (ja) 2008-09-11
RU98117628A (ru) 2000-08-20
FI982413A (fi) 1998-11-06
HU0500355D0 (en) 2005-05-30
AU4973093A (en) 1994-03-29
DK0658161T3 (da) 1999-11-29
NO2001006I1 (no) 2001-04-30
GR3030794T3 (en) 1999-11-30
MY111190A (en) 1999-09-30
MA22970A1 (fr) 1994-04-01
JPH11147885A (ja) 1999-06-02
ES2133410T3 (es) 1999-09-16
SG83747A1 (en) 2001-10-16
ZA936509B (en) 1994-06-16
CN1183413A (zh) 1998-06-03
CN1183276A (zh) 1998-06-03
LU90712I2 (fr) 2001-03-12
CZ287473B6 (en) 2000-12-13
US5910592A (en) 1999-06-08
IL106904A (en) 1997-09-30
RU95108329A (ru) 1996-12-20
KR100371297B1 (ko) 2003-05-09
CN1101911A (zh) 1995-04-26
HU9500659D0 (en) 1995-04-28
SK280777B6 (sk) 2000-07-11
PL173725B1 (pl) 1998-04-30
FI982413A0 (fi) 1998-11-06
FI951004A (fi) 1995-03-03
KR950702982A (ko) 1995-08-23
JPH08501095A (ja) 1996-02-06
NZ255505A (en) 1997-08-22
HU224212B1 (hu) 2005-06-28
NO950852D0 (no) 1995-03-03
CN1040323C (zh) 1998-10-21
SG48302A1 (en) 1998-04-17
PL307812A1 (en) 1995-06-26
CN1051312C (zh) 2000-04-12
KR20080081099A (ko) 2008-09-05
CA2273147A1 (en) 1994-03-17
JP2828777B2 (ja) 1998-11-25
SI9300452B (sl) 2003-02-28
NO303016B1 (no) 1998-05-18
CZ56595A3 (en) 1995-11-15
SI9300452A (en) 1994-06-30
MX9305397A (es) 1995-01-31
ATE182147T1 (de) 1999-07-15
FI951004A0 (fi) 1995-03-03
BR1100916A (pt) 2000-07-04
RU2128179C1 (ru) 1999-03-27
FI106263B (fi) 2000-12-29
NO2001005I2 (no) 2004-06-01
CN1066939C (zh) 2001-06-13
HK1012363A1 (en) 1999-07-30
JP2002047288A (ja) 2002-02-12
NO305802B1 (no) 1999-07-26
GB9218830D0 (en) 1992-10-21
DE69325658D1 (de) 1999-08-19

Similar Documents

Publication Publication Date Title
RU98117673A (ru) Фармкомпозиция для лечения и/или профилактики гипергликемии, соль малеиновой кислоты 5-[4-[2-(n-метил-n-(2-пиридил)амино) этокси] бензил] тиазолидин-2, 4-диона или ее изомерная или таутомерная форма для лечения диабета ii типа
RU93043528A (ru) Моногидрат 5-(2-(4-(1,2-бензотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2н-индол-2-он хлоргидрата, способ его получения, фармацевтическая композиция, способ лечения
KR940006590A (ko) 알쯔하이머 질환 치료용 및 혈당저하제로서 유용한 화합물
EA200601145A1 (ru) Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов
CA2585898A1 (en) Use of (2s,3s,5s)-5-(n-(n-((n-methyl-n-((2-isopropyl-4-thaizolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(n-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane in combination with another protease inhibitor for treating hiv infection
MY129897A (en) Use of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2, 4-dione and metformin for the treatment of diabetes mellitus
NZ504703A (en) Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
HUP0100509A3 (en) 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical, process for its preparation and its pharmaceutical use
UY25102A1 (es) Nueva composición para el tratamiento de diabetes mellitus
DE69033926D1 (de) Verwendung von Piperazin-Acetamid-Derivaten gegen Reperfusionsschaden
HUP0100500A2 (hu) Az 5-[4-{2-[N-metil-N-(2-piridil)-amino]-etoxi}-benzil]-2,4-dioxo-tiazolidin-maleinsav-só hidrátja, eljárás az előállításukra és gyógyászati alkalmazása
MY135973A (en) Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative
HUP0003260A2 (hu) Gyógyszerkészítmény diabetes kezelésére rosziglitazonnal és inzulinnal
NZ513922A (en) Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione
MY119071A (en) Crop protection products
UY26112A1 (es) Dihidrato de hidrocloruro de 5- [4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidina-2,4-diona
NZ515555A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
AP1600A (en) Combination of a thiazolidinedione and a sulphonylurea for treating diabetes
UY25051A1 (es) Composiciones para el tratamiento de diabetes mellitus
AP1715A (en) The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione
DE60212434D1 (de) Rosiglitazon-edisylate und ihre verwendung als antidiabetika
AP2002002673A0 (en) Thiazolidinedione salt for the treatment of diabetes mellitus.
HK1057751A1 (en) A thiazolidinedione derivative and its use as antidiabetic
AP1841A (en) A thiazolidinedione derivative and its use as antidiabetic.
NZ524933A (en) Sodium salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and pharmaceutical composition thereof

Legal Events

Date Code Title Description
FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20050120

FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20060110